Davita Inc (DVA) 2026 Annual Meeting

BA BRIEFING·
Davita Inc (DVA) 2026 Annual Meeting
9 directors up · 2 in watch zone · 3 proposals · Uncontested
$12.7B mkt cap · 1Y TSR +40.9% · Board B
Director Elections (9) · 9 of 9 scored by BA forecast
Election Outlook
Most directors look set to be re-elected without meaningful dissent — 7 of 9 scored nominees are rated Healthy. Two are worth watching: Phyllis R. Yale (prior 99.7%, forecast Watch) and Pamela M. Arway (prior 97.5%, forecast Watch).
NomineeForecastBackground
Independent
WATCH
Prior 97.5%
70808793100
Pamela Arway served as CEO of American Express Australia Limited from 2004 to 2005 and has been Independent Chairperson of Iron Mountain's Board since 2022.
Independent
HEALTHY
Prior 98.3%
70808793100
Barbara J. Desoer served as CEO of Citibank, N.A. from 2014 to 2019 and led the integration of Countrywide at Bank of America.
Independent
HEALTHY
Prior 98.8%
70808793100
Jason Hollar has served as CEO of Cardinal Health since September 2022 and was previously CFO of Tenneco and Sears Holding Corporation.
Independent
HEALTHY
Prior 99.9%
70808793100
Gregory J. Moore led Microsoft Health and Life Sciences from 2019 to 2023 and founded Google Cloud Healthcare and Life Sciences from 2016 to 2019.
Independent
HEALTHY
Prior 99.9%
70808793100
Dennis W. Pullin has served as President and CEO of Virtua Health since 2017 and was previously President of MedStar Harbor Hospital from 2009 to 2017.
Not independent
HEALTHY
Prior 99.9%
70808793100
Javier J. Rodriguez has served as CEO of DaVita Inc. since June 2019 and has been on the board of Gilead Sciences, Inc. since June 2020.
Independent
HEALTHY
Prior 99.6%
70808793100
Adam H. Schechter has served as President and CEO of Labcorp since November 2019 and was previously President, Global Human Health at Merck from 2010 to 2018.
Independent
HEALTHY
Prior 99.6%
70808793100
Wendy L. Schoppert served as Executive Vice President and CFO of Sleep Number Corporation from 2011 to 2014 and currently serves on the Board of Directors of Sun Country Airlines and Fossil Group.
Independent
WATCH
Prior 99.7%
70808793100
Phyllis R. Yale served as Chair of the Blue Cross Blue Shield of Massachusetts Board from 2014 to 2019 and has been on the board of Bristol Myers Squibb since November 2019.
Proposals on the Ballot (3)
#1
Election of Directors
Filed by the board · Board recommends For
Elect nine director nominees each to serve until the 2027 Annual Meeting or until their successors are duly elected and qualified.
#2
Ratification of Appointment of Independent Registered Public Accounting Firm (KPMG LLP
Filed by the board · Board recommends For
Ratify the Audit Committee’s appointment of KPMG LLP as DaVita’s independent registered public accounting firm for fiscal year 2026.
#3
Advisory Vote to Approve Named Executive Officer Compensation (Say-on-Pay
Filed by the board · Board recommends For
An advisory, non-binding vote to approve the compensation of the Company’s named executive officers as disclosed in the Proxy Statement.
Detail ›
This proposal asks stockholders to cast an advisory (non-binding) vote approving the Company’s named executive officer (NEO) compensation as disclosed in the Proxy Statement. Management is seeking shareholder approval to confirm that its compensation design — which emphasizes a high proportion of at-risk pay tied to short-term and long-term performance metrics (including Adjusted Operating Income, Free Cash Flow, Adjusted EPS and Relative TSR), and a mix of PSUs, RSUs and SSARs — aligns executives’ incentives with the Company’s strategic objectives and stockholder interests. The Compensation Committee frames the program as pay-for-performance with formulaic STI and PSU metrics, and retains limited discretion only to apply negative adjustments; it also emphasizes share ownership requirements, clawback policies, double-trigger change-of-control provisions and other governance features. The context includes recent operational developments (IKC profitability, international expansion, cybersecurity incident response) and strong stockholder engagement and prior high say-on-pay votes, which management cites to justify continuation of the program. The vote is advisory and non-binding, but the Board and Compensation Committee commit to considering the results when making future compensation decisions. A failure to approve would not automatically change pay arrangements but would likely trigger heightened engagement with major investors and could prompt the Compensation Committee to redesign elements of the program to better reflect stockholder concerns. Given the company’s disclosure of robust performance metrics, multi-year incentives, and safeguards against excessive risk-taking, the Board recommends a FOR vote because it believes approval supports continuity of an executive compensation framework that it views as focused on long-term value creation and alignment with stockholders. The analysis for sophisticated investors should weigh the program’s heavy reliance on equity-based awards (sensitive to stock price movements), the mechanics of PSU adjustments (including permitted pre-established adjustments), and the broader governance practices (independent Compensation Committee, independent chair, recoupment policies) when assessing whether the advisory endorsement appropriately reflects stockholder interests.
Top institutional holders · as of Mar 31, 2026
Holder% of sharesPosition value
BERKSHIRE HATHAWAY INC23.56%$2.32B
BERKSHIRE HATHAWAY INC23.32%$2.30B
VANGUARD CAPITAL MANAGEMENT LLC3.40%$335M
VANGUARD PORTFOLIO MANAGEMENT LLC2.30%$227M
STATE STREET CORP2.11%$208M
Invesco Ltd.2.06%$204M
BlackRock, Inc.2.06%$203M
ARROWSTREET CAPITAL, LIMITED PARTNERSHIP1.73%$171M
DIMENSIONAL FUND ADVISORS LP1.66%$164M
LSV ASSET MANAGEMENT1.45%$143M
Source: SEC 13F filings (latest quarter). Position value is the holder’s reported aggregate value at the as-of date.
Recent key filings
Quarterly report (10-Q)View ›
Definitive proxy (DEF 14A)View ›
Annual report (10-K)View ›
Quarterly report (10-Q)View ›
Quarterly report (10-Q)View ›
Definitive proxy (DEF 14A)View ›
About the risk forecast

The risk forecast scores each director on the company’s slate against Boardroom Alpha’s YoY Director-Vote Forecast model — three XGBoost classifiers that estimate the probability the director’s vote support falls below 70%, 80%, and 90% at the upcoming annual meeting, augmented by a five-rule governance escalation layer (overboarding, audit-committee composition, prior dissent, and others).

Bands map to those probability thresholds:

  • Crisis — high probability of vote support below 70%. Rare.
  • Material — high probability of below 80%. The primary screening threshold.
  • Elevated — significant elevated risk of dissent.
  • Watch — even a mild withhold is detectable. Informational.
  • Healthy — no signal of meaningful dissent.

Prior is the director’s most-recent vote-support percentage at this same board. Direction compares the forecast to that prior vote: ↑ expected better means more support than last year; ↓ expected worse means less.

Forecast applies only to non-contested annual proxies (DEF 14A). Contested situations are tracked separately on the contested-proxy pipeline. The model is retrained nightly; bands shown reflect the most recent run.

« Back to Shareholder Meeting Calendar

Get this in your inbox
Activism and governance research, in your inbox
Director nominee slates, proposals, settlement campaigns, and AGM outcomes from US public companies.

Frequently Asked Questions

When is the Davita Inc 2026 annual meeting?
Davita Inc (DVA) holds its 2026 annual shareholder meeting on June 4, 2026.
What is the record date for the Davita Inc 2026 meeting?
The record date for the Davita Inc 2026 meeting is April 9, 2026. Shareholders of record on or before that date are eligible to vote.
Who are the director nominees for Davita Inc's 2026 meeting?
The board is presenting 9 director nominees at the Davita Inc 2026 meeting. The full slate appears in the 'Director Nominees' table on this page, with independence designations and a structured indexable summary.
What proposals will shareholders vote on at the Davita Inc 2026 meeting?
Shareholders will vote on 3 proposals at the Davita Inc 2026 meeting. The full list with proposed-by tags and management recommendations appears in the 'Proposals on the Ballot' section on this page.
Are any directors at risk at Davita Inc's 2026 annual meeting?
The Boardroom Alpha Director-Vote Forecast flags 2 of 9 scored nominees as facing elevated vote pressure at the Davita Inc 2026 meeting: Pamela M. Arway, Phyllis R. Yale. The most-loaded nominee is Phyllis R. Yale (forecast band: watch). Prior support: 99.7%. See the 'Director Nominees' table for the per-director forecast bar and prior support.
Where do I find the original proxy filing?
The 'View proxy' link at the top of this page opens the original SEC DEF 14A (or amended) filing for the Davita Inc 2026 meeting in the Boardroom Alpha filing viewer.

Last updated: